"Combining our strengths to address the unmet medical needs of patients who are desperately waiting for solutions."
ABOUT
INSILICO MEDICINE + A2A PHARMA
Consortium.AI - the joined force to apply the latest advances in AI to discovery of novel small molecules for the Duchenne Muscular Dystrophy (DMD) and other rare orphan diseases.
Consortium AI will bridge the ecosystems of two rapidly expanding AI-companies to enable dramatically faster and less expensive development of more effective therapeutics.
Duchenne muscular dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3 and 5.

Currently, there is no effective curative treatment for DMD and as with the other genetic disorders resulting in muscular dystrophy the search for drug targets is extremely challenging.